-
Mashup Score: 0Disease-Modifying Therapies in Progressive Multiple Sclerosis - 2 year(s) ago
Key presentations at CMSC 2022 included use of BTK inhibitors in MS, results from the DISCOMS trial, and immune response of MS patients vaccinated for COVID-19, as reported by Dr Robert Shin.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1COVID vaccination in DMT-treated MS patients: New data - 2 year(s) ago
Antibody responses were assessed in patients under treatment.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
The latest updates on COVID-19 vaccination response among MS patients treated with DMT show that, if patients do contract the virus, cases are mild and serious infections are rare. https://t.co/qVjitzXS9r #CMSC2022 https://t.co/5LGes0QLeR
-
-
Mashup Score: 2Risk of drug interactions is on the rise as MS drugs evolve - 2 year(s) ago
Newer medications pose more danger, pharmacist says, and require more awareness.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
About 1 in 25 #MS patients face a potentially severe interaction with their prescribed medications putting them at risk of adverse effects that may lead to secondary comorbidities and therapeutic failures. https://t.co/tNs2jaHKn7 #CMSC2022 https://t.co/TPlVFAUW8I
-
-
Mashup Score: 0Consider the wider picture in relapsing remitting MS - 2 year(s) ago
The best medication for a patient may not have highest efficacy, one expert says.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
Knowledge about RRMS medications and a patient’s personal circumstances + their comorbidities help personalize treatment. https://t.co/Z1WJiGIW3l #CMSC2022 https://t.co/BdCqsG0lra
-
-
Mashup Score: 1Risk of Drug Interactions on the Rise as MS Treatments Evolve - 2 year(s) ago
In a new study of more than 600 patients with multiple sclerosis, about 1 in 25 faced a potentially severe drug-drug interaction, with more having at least one potentially risky interaction.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet-
How often do MS patients end up on meds that have the potential to interact dangerously with other medications they're taking? https://t.co/eXRzOSBIUw #CMSC2022
-
-
Mashup Score: 0Risk of drug interactions is on the rise as MS drugs evolve - 2 year(s) ago
Newer medications pose more danger, pharmacist says, and require more awareness.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
About 1 in 25 MS patients face a potentially severe interaction with their prescribed medications putting them at risk of adverse effects that may lead to secondary comorbidities and therapeutic failures. https://t.co/g3k5WRw2zZ #CMSC2022 https://t.co/cEBovCLwIV
-
-
Mashup Score: 0Novel Drug Safe, Effective in Relapsing MS: 2-Year Data - 2 year(s) ago
The investigational evobrutinib, an Bruton’s tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet-
Evobrutinib, an investigational BTK inhibitor for RMS, is relatively safe and effective over the long-term, new research suggests. https://t.co/Mm5dCbrL7a #CMSC2022
-
-
Mashup Score: 0
Costly procedures help some patients but where to draw the line is unclear.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
Positive data support aHSCT as an option for MS patients who have failed other disease-modifying options. The challenge remains in determining whether transplant is an alternative to the high-efficacy DMTs in some high-risk patients. https://t.co/rrROoPdbhv #CMSC2022 https://t.co/gqxhqvUkr8
-
-
Mashup Score: 0Inebilizumab Beneficial Across Genotypes in NMOSD - 2 year(s) ago
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet-
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests. https://t.co/GU7fvgn3oJ #CMSC2022
-
-
Mashup Score: 0Non-White subjects are sparse in DMT trials for MS - 2 year(s) ago
Black people only made up 1.9% of participants in studies reporting full racial data over 25 years.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
Phase 3 trials of DMTs for MS were overwhelmingly made up of White subjects and many studies failed to report percentages of non-White subjects at all. https://t.co/eSxXHsB3z7 #CMSC2022 https://t.co/UsmALcwnjV
-
Dr Robert Shin, from @MedStarGUH, highlights key presentations in DMT for MS presented at #CMSC2022. https://t.co/KaG5Vg3fPA https://t.co/1aViX7xP2I